企業プロフィール
Halozyme Therapeutics, Inc. 株価・ニュース・カタリスト
- ティッカー:
- HALO
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
103.00 USD (+4.40%)
終値
最終更新: 2026年8月17日
7.86B USD
時価総額
株価変動の要因
As of Aug 17, 2026, HALO closed up 4.40% at $103.00. No new same-company headline was identified in the current news window.
企業概要
事業概要
Halozyme Therapeutics is a biopharmaceutical company best known for its enzyme technology platform that enables subcutaneous drug delivery. The business combines licensed technology revenue with development activity around oncology and other therapeutic areas.
所在地とセクター分類
Headquartered in the United States and listed on NASDAQ, Halozyme is a U.S.-based specialty biotech company. It sits in platform-enabled drug delivery and oncology-adjacent therapeutics.
ビジネスモデルの特徴
The company generates value through royalty income, partner relationships, and technology licensing tied to subcutaneous formulation. Investors follow licensing growth, partner adoption, and whether the technology platform continues to expand across the industry.
バイオ業界での位置付け
Halozyme occupies a unique position in biotech because it monetizes platform technology rather than relying only on its own clinical pipeline. That makes it less binary than many development-stage peers, but still catalyst-sensitive around deal flow and partner uptake.
今後のカタリスト
- Halozyme's catalysts are partner launches on the ENHANZE platform, especially Darzalex Faspro and VYVGART Hytrulo royalty growth, plus any new subcutaneous-drug-delivery deal. The stock moves when royalty durability and partner breadth both keep expanding.
最近のニュース
- 01
- 02
- 03
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。